Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment
Open Access
- 1 February 2024
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 42, 101883
Abstract
No abstract availableKeywords
Funding Information
- James Graham Brown Foundation
- Biorad Inc
- National Institutes of Health (P20GM135004)
This publication has 48 references indexed in Scilit:
- Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort studyJournal of the American Academy of Dermatology, 2016
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid BiopsyCancer Discovery, 2016
- Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitorsJournal of Translational Medicine, 2016
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsClinical Cancer Research, 2016
- Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanomaOncotarget, 2015
- Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF InhibitorsClinical Chemistry, 2015
- BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapyEuropean Journal of Cancer, 2014
- Value of positron emission tomography scan in stage III cutaneous melanoma: A systematic review and meta-analysisSurgical Oncology, 2014
- Marginal association measures for clustered dataStatistics in Medicine, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009